- Center on Health Equity and Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Segment 3: The Trouble with Prognostic Tests
Payers differentiate between predictive and prognostic diagnostic tests, and one is definitely more useful than the other, according to John L. Fox, MD, MHA, of Priority Health, and Bryan Loy, MD, MBA, of Humana.
Payers differentiate between predictive and prognostic diagnostic tests, and one is definitely more useful than the other, according to John L. Fox, MD, MHA, of Priority Health, and Bryan Loy, MD, MBA, of Humana.
In the predictive space, payers are looking to see if a specific biomarker can be used to predict whether or not a drug will produce better outcomes in certain patient populations, and there is good evidence of clinical utility, according to Dr Fox.
He and Dr Loy agree, though, that having the evidence of an association between a test and an outcome isn’t enough because whether or not the information is being used correctly is often unstudied.
“Having the study doesn’t necessarily mean that we’re going to get the value out of those tests as a payer,” Dr Loy said. “Having a good test in the wrong hands or if the information never gets utilized, there is not value for us.”
Perioperative Nivolumab Boosts NSCLC Survival: CheckMate 77T Trial
May 16th 2024This interim analysis of the CheckMate 77T trial, outcomes were compared between adult patients receiving neoadjuvant nivolumab plus chemotherapy or neoadjuvant chemotherapy plus placebo for resectable non–small cell lung cancer (NSCLC).
Read More
CMS Medicare Final Rule: Advancing Benefits, Competition, and Consumer Protection
May 7th 2024On this episode of Managed Care Cast, we're talking with Karen Iapoce, senior director of government products and programs at ZeOmega, about the recent CMS final rule on Medicare Part D and Medicare Advantage.
Listen
Congress Urged to Repeal Comstock Act Threatening Reproductive Rights and Public Health
May 16th 2024In a joint letter addressed to Congress, Healthcare Across Borders, Take Back the Court Action Fund, and UltraViolet Action called out the resurgence of the Comstock Act, urging immediate action to repeal this century-old law that threatens reproductive rights and public health in the US.
Read More
